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Abstract 
Resistance to antimicrobials is one of the biggest threats to our healthcare. However, 
in the last few decades very few truly novel antimicrobial compounds have been 
brought to market, creating the potential threat of a post-antibiotic era in which 
infections are very difficult to treat. Identification of novel compounds with 
antimicrobial activity is therefore paramount. Ideally, novel compounds should be 
designed that are active against targets that are not or barely used, as it is less likely 
that resistance already exists against such compounds. One example of an 
underexplored target in the treatment of infections is DNA. In this review we describe 
a number of DNA binding compounds and discuss potential opportunities and 
problems.   
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1. Introduction 
Antibiotics play an essential role in the treatment of bacterial infections, but this has 
become more and more problematic due to the emergence of multidrug resistant 
pathogens. Indeed, the Chief Medical Officer of the UK, Dame Sally Davies, in 2013 
called antibiotic resistance a health catastrophe, ranking similarly to terrorism and 
climate change [1]. Well-known examples of bacteria that create significant problems 
are extended spectrum beta-lactamase (ESBL) producing Gram-negative bacteria, 
multidrug-resistant Mycobacterium tuberculosis and meticillin-resistant 
Staphylococcus aureus (MRSA). For instance, production of ESBL is the most 
common resistance mechanism for 3rd generation cephalosporins and, worryingly, 
resistance of Escherichia coli isolates to these cephalosporins in Europe has risen by 
8-fold in the period from 2002-2011 (Fig. 1a). Some positives should however also be 
noted, with meticillin resistance in S. aureus gradually decreasing since its peak in 
2003-2005 (Fig. 1b). Note however that the occurrence of MRSA is still high, with 
some European countries such as Portugal and Romania reporting around 50% of S. 
aureus isolates being meticillin resistant in 2011. 
  
Fig. 1. Antibiotic resistance of clinical isolates in Europe. (A) Percentage of 3rd generation 
cephalosporin-resistant E. coli isolates, and (B) percentage of meticillin-resistant S. aureus isolates. 
Data were collected from the EARS-Net Database, http://www.ecdc.europa.eu/en/healthtopics/ 
antimicrobial_resistance/database/Pages/table_reports.aspx). 
A                                                             B
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 It is thus clear that it is crucial to develop new antibiotics and remain ahead of 
antibiotic resistance in pathogenic bacteria. Antibiotics that are currently used 
clinically have only a limited set of targets. These include the cell wall (targeted by 
penicillins, cephalosporins, glycopeptides), the cell membrane (polymyxins, 
daptomycin), ribosomes (aminoglycosides, macrolides and tetracyclines), as well as a 
small set of essential enzymes: RNA polymerase (rifamycins), DNA gyrase and 
topoisomerase (quinolones), and dihydropteroate synthetase (sulphonamides). A huge 
problem is that hardly any novel classes of antibiotics have been developed in the last 
few decades, with a few notable exceptions being daptomycin and linezolid. Most 
new antibiotics coming onto the market are variants of existing drugs, which carries 
the risk that (partial) resistance to such drugs already exists.  
 
There are many potential antimicrobial targets in bacteria, several of which are not or 
hardly utilised in the treatment of infections. One target that has recently been 
addressed in a number of studies is DNA. This target may seem at first sight not very 
useful, as DNA-binding compounds would not only inhibit the growth of bacteria, but 
also that of eukaryotes. If, however, there is some way towards establishing 
specificity, then DNA may indeed be an attractive target. This issue is discussed 
towards the end of this review. Note also that there are already a few DNA-targeting 
antimicrobials on the market (see below), and further expansion of the repertoire of 
DNA-binding antimicrobials for clinical use thus seems most certainly conceivable. 
 
Binding of compounds to DNA occurs through a number of mechanisms, which can 
be broadly divided into covalent and non-covalent interactions. Covalent interactions 
are the strongest and involve modification of DNA through alkylation. Non-covalent 
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interactions mainly involve intercalation between bases, or binding to the major or 
minor groove of the DNA helix [2-4]. In some cases, interaction of compounds with 
DNA may also result in damage of the DNA, and lead to for instance single or double 
strand breaks. All of these interactions are likely to interfere with enzymes (e.g. 
polymerases, topoisomerases) and essential processes of transcription, replication and 
repair, thus leading to cell death. In this review, we will consider a number of 
compounds of interest, with a particular focus on those with antimicrobial activity, 
and then discuss whether there is a future in the clinical use of DNA binding 
compounds as antimicrobial therapeutics. 
 
2. DNA Intercalators 
Several organisms produce antimicrobial compounds as a means of competing with 
other organisms in their environment. Many of those that are used clinically originate 
from Gram-positive soil bacteria belonging to the genus Streptomyces, including 
streptomycin, vancomycin, daptomycin and tetracycline. Initial work on the isolation 
of compounds from Streptomyces spp. was conducted in the laboratory of Selman 
Waksman, who received recognition for his work with the Nobel Prize for Physiology 
or Medicine in 1952. Some of first compounds isolated were actinomycins [5], with 
most of the later research being performed on actinomycin D (compound 1; also 
called dactomycin). This compound (Fig. 2) contains a planar tricyclic phenoxazone 
ring that intercalates double stranded DNA, and two cyclic pentapeptide lactone rings 
that interact with the minor groove above and below the intercalated phenoxazone 
ring. However, it has a strong preference for DNA that is partially unwound, such as 
found in transcription bubbles [6]. As a consequence, actinomycin D blocks RNA 
synthesis, leading to cell death. The molecule has both antibiotic and anticancer 
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activity; because of the latter, the compound is too toxic for the treatment of 
infections. However, the compound has been used for many years as an anticancer 
agent, mainly in the treatment of paediatric cancers such as Wilms’ tumour and 
rhabdomyosarcoma [7]. In addition, its activity as a transcription inhibitor has also 
been exploited as useful tool in molecular biology. 
 
Fig. 2. Structure of actinomycin D (1). The intercalating phenoxazone group is indicated in red. 
 
Another family of naturally produced compounds interacting with DNA are bis-
intercalators [8] that includes for instance echinomycin (2), triostin A and 
sandramycin. Many of these are isolated from Streptomyces spp., but some are 
produced by other bacteria. All of these contain a peptide core that that is decorated 
with two intercalating planar aromatic groups, being quinoxaline-2-carboxylic acid in 
echinomycin and triostin A, or 3-hydroxyquinaldic acid in sandramycin [9].  
Echinomycin (Fig. 3) has been tested in a number of phase I and II clinical trials 
against different types of cancer, but the majority of those did not show a significant 
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effect [10-12]. One of the exceptions was a study on colorectal cancer, where a 
moderate activity was observed [13]. In more recent years there has been a renewed 
interest in echinomycin as an antimicrobial agent. For instance, it has been shown to 
be effective against clinical isolates of MRSA [14]. That study demonstrated that 
echinomycin (2) is more effective than vancomycin (one of the few antibiotics used 
clinically to treat MRSA infections), not only in vitro but also in vivo in a mouse 
model. Echinomycin has also been demonstrated to be active against other microbes, 
including vancomycin resistant enterococci (VRE) [15] and the parasitic protozoan 
Entamoeba histolytica [16]. A problem of echinomycin is that it is rather hydrophobic 
and not particularly soluble in water. For that purpose polar derivatives were designed 
[15]. Unfortunately, these were less effective in vitro than echinomycin; the minimal 
inhibitory concentration (MIC) of echinomycin against clinical isolates of enterococci 
was found to be in the range of 0.03-0.25 µg/mL, while that was 0.5-8 µg/mL for the 
better of the two derivatives (denoted YK2000). However, infections with VRE are 
particularly difficult to treat because of the multi-drug resistant nature of these 
bacteria, and YK2000 could still be considered for therapeutic use. 
 
 
Fig. 3. The structure of echinomycin (2) with the intercalating groups in red. 
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Antibiotics belonging to the anthracycline family form another large group of well-
known DNA intercalators. These include the naturally produced compounds 
doxorubicin and daunorubicin (produced again by Streptomyces spp.), or (semi) 
synthetic derivatives thereof such as epirubicin. These compounds are antibacterial, 
but they also have a particularly strong cytotoxic activity. These anthracyclines are 
therefore not suitable in the treatment of bacterial infections, but several are used in 
the treatment of various types of cancer. More recently, amino-sugar functionalised 
anthracycline analogues have been made that were tested for antibacterial activity 
[17]. The compounds were active against a Gram-positive bacterium (Bacillus 
atropheus) but not against a Gram-negative bacterium (E. coli). The activity found 
correlated to a large extend with the DNA binding activity, but all of the compounds 
isolated had an antibacterial activity lower than that of daunorubicin or doxyrubicin. 
 
While the compounds mentioned above are all produced naturally or analogues 
thereof, also a number of fully synthetic intercalators have been produced. Some of 
the earliest work on this was on a coordination complex of ruthenium with the ligand 
1,10-phenanthroline (phen), [Ru(phen)3]2+ [Ref 18], where this complex demonstrated 
activity against Gram-positive bacteria. The same group also performed more detailed 
studies with additional ligands (e.g. 2,2'- bipyridine) and metals (Ni(II),  Cu(II), Fe(II) 
and Co(II) (compounds 3 and 4, Fig 4), and tested these on a larger panel of bacteria 
[18, 19]. These complexes were more active against Gram-positive bacteria than 
Gram-negative bacteria. Pathogenic bacteria such as Mycobacterium tuberculosis, 
Erysipelothrix rhusiopathiae, S. aureus and E. coli, as well as the fungi Candida 
albicans and Trichophyton mentagrophytes, did not develop resistance of any 
significance to metal complexes of phenanthroline based ligands and the 
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susceptibility of S. aureus and E. coli appeared to be independent of the antibiotic-
resistance pattern of the organism [20]. In vivo (using mice or guinea pig models) the 
compounds were found not to be effective when administered parenterally, but some 
proved useful in the topical treatment of bacterial infections [19, 20]. This was 
however not taken forward and these compounds have not been used clinically. 
!  
Fig. 4.  Some of the transition metal complexes (3 and 4) investigated by Dwyer which demonstrated 
bacteriostatic and bacteriological activity 
 
Recently, we and others revisited some of this work, where the antibacterial activity 
of a number of Ru(II) complexes (for examples, see Fig. 5) with proven DNA binding 
were evaluated [21-23, and references therein]. We used compounds with the general 
structure [Ru(PL)2(IL)]2+, where PL is a peripheral ligand, and IL the intercalating 
ligand. Of the compounds tested, the order of the antimicrobial activity followed the 
order of the affinity of the intercalating ligands for DNA, consistent with a DNA-
binding mode of action.  The compounds performed poorly against Gram-negative 
bacteria, but showed good activity against Gram-positive bacteria, including clinical 
multidrug resistant isolates such as MRSA. The most active compound that we 
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identified was [Ru(2,9-Me2phen)2(dppz)]2+ (where 2,9-Me2phen = 2,9 dimethyl-1,10-
phenanthroline, and dppz = dipyrido[3,2-a:2'3'-c]phenazine) (complex 5, Fig. 5). 
Interestingly, the compound was also active in an infection model [21]. In the absence 
of compound, the soil nematode Caenorhabditis elegans was killed within a few days 
by MRSA, but the presence of [Ru(2,9-Me2phen)2(dppz)]2+ rescued the nematodes 
from infection. This firstly demonstrated that the complex was active in vivo. In 
addition, it showed that the concentrations used were not toxic to the nematodes, 
although it should be noted that the lethal dose for nematodes was not determined. 
The nematodes served are only a very simple model system, but it should be noted 
that: (a) these organisms share several features with higher animals and have neurons, 
muscles, intestines, epidermis; (b) they have an innate immune response system; and 
(c) indeed they have been demonstrated to be a very useful model system for several 
human pathogens [24]. 
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Fig. 5.  Some of DNA binding antibacterial complexes (5, 6 and 7). 
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 Other mononuclear intercalating complexes like complex 6 (Fig. 5) have also shown 
antibacterial and antifungal activity against E. coli and Neurospora crassa with zones 
of inhibition (in disk sensitivity tests; 20µg per disk) of 10 and 7 mm [23]. Chiral 
dinuclear compounds have also demonstrated antibacterial activity against Gram-
positive bacteria, including MRSA (complex 7, Fig. 5). Dinuclear complexes of this 
type have been reported to bind to bulge sites of DNA. More recently an example [{Ru(phen)2}2{u7bb7}]4+!(where!bb7=!bis[4(4'7methyl72,2'7bipyridyl)]71,77alkane) has been shown to bind chromosomal DNA of S. aureus [22]. 
 
Cobalt complexes of phenanthroline and of multidentate ligands (complex 8, Fig. 6) 
were also investigated by Dwyer and showed bacteriostatic and bactericidal 
properties. Other cobalt complexes (complex 10-13, Fig. 6) that have been more 
recently developed and have demonstrated considerable activity against S. aureus, 
Bacillus subtilis, E. coli and Pseudomonas aeruginosa. While the hydrophobicity 
imparted by the alkyl chain may result in membrane damage, DNA binding was also 
suggested as a mode of action. Complexes of [Co(en)2IL2] (where en = 
ethylenediamine and IL = 2,2'-bipyridine (9a), 1,10 phenanthroline (9b), imidazole 
(9c), methylimidazole (9d), ethylimidazole (9e) or dimethylimidazole (9f)) (Fig. 6) 
have also been reported to show activity against several bacteria (E. coli, Salmonella 
typhimurium, Proteus vulgaris, P. aeruginosa, S. aureus, Enterococcus faecalis and 
B. subtilis). Their mode of action was not discussed but the parent complex 
[Co(en)3]2+has been demonstrated by NMR to interact with DNA [25, 26].  
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Fig. 6. Structures of Cobalt coordination complexes (8-13) 
 
We also tested several coordination complexes of Cu(II), and found these to be not 
only active on Gram-positive bacteria such as MRSA, but also on Gram-negative 
bacteria. For instance, the activity of  [Cu-56MESS]2+ (56-MESS  = (5,6-dimethyl-
1,10-phenanthroline)(1S,2S-diaminocyclohexane); complex 14, Fig. 7) was similar for 
both MRSA and E. coli, with an MIC of 8 µg/mL [27]. No activity against the Gram-
negative bacterium P. aeruginosa was found. However, that is an organism with a 
high level of innate resistance against many compounds, in part due to its much lower 
outer membrane permeability (~8%) compared to that of E. coli [28]. A problem with 
some of the copper compounds tested was their toxicity, as confirmed by activity 
against a mammalian cell line (L1210) and toxicity against C. elegans nematodes 
[27]. However, some of the copper complexes had a low toxicity against nematodes, 
while still retaining a reasonable antimicrobial activity, suggesting that further 
development may lead to identification of compounds with low toxicity and high 
antimicrobial activity. 
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Other copper compounds that incorporate a 1,10-phenanthroline, cyanoguanidine, 
bipyridines, terpyridines and/or antibiotics have recently been evaluated for their 
activity. The complex [Cu(phen)(cyanoguanidine)(H2O)(NO3)]NO3 (complex 15, Fig 
7) [29] was synthesised to explore the effect of combining the nitrogenase substrate 
cyanoguanidine with copper and phenanthroline against E. coli, S. aureus, E. faecalis 
and P. aeruginosa. The most significant activity was observed against S. aureus and 
E. faecalis with MIC values of 24 µg/mL for both organisms, as compared to 375 
µg/mL for CuCl2.2H2O (both organisms) and 24 (S. aureus) and 94 µg/mL (E. 
faecalis) for phenanthroline [29]. 
 
As a strategy to circumvent antibacterial resistance and improve solubility, the FDA 
approved broad-spectrum antibiotics (B-SA), iomefloxacin  (complex 16, Fig. 7) [30] 
or ciprofloxacin (complexes 17 and 18, Fig. 7) [31-33]. These antibiotics, which 
function by inhibition of one step in DNA gyrase activity, were coordinated to copper 
complexes with the general structure [Cu(B-SA)(IL)(NO3 or Cl)]+, where B-SA is 
iomefloxacin (red) or ciprofloxacin (blue), and ILs with the potential to intercalate are 
1,10-phenathroline [30], 4-(R-phenyl)-6-phenyl-2,2'-bipyridine [31, 32], or 2,2':6',2''-
terpyridine [33]. Examples of the resulting copper complexes 16-17, shown in Fig 7, 
had demonstrated activity, with MIC values all in the range of 0.3-2.6 µM, against 
both Gram positive (S. aureus and B. subtilis) and Gram negative (E. coli, Serratia 
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marcescens and P. aeruginosa) bacteria.
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Fig. 7. Structures of copper coordination complexes (14-18) 
 
With these metal complexes it should be noted that the potential to bind DNA does 
not necessarily lead to antibacterial activity. For instance, complexes of [Pt(IL)Cl2] 
where ILs are derivatives of phenanthroline such as 1,10-phenanthroline-5,6-dione 
(19, Fig. 8) or dppz = dipyrido[3,2-a:2'3'-c]phenazine (20) can intercalate or 
coordinate to DNA. However, antibacterial activity against E. coli, B. subtilis or 
Streptomyces coelicolor was not evident [34]. This suggests that DNA binding alone 
is not sufficient to induce antibacterial activity but that the mode of interaction is 
important.  
 !!!
Fig. 8. Platinum complexes of the general structure of [Pt(IL)Cl2] ] where ILs =1,10-phenanthroline -
5,6-dione (19) or dppz = dipyrido[3,2-a:2'3'-c]phenazine (20). 
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3. Minor Groove binders 
Another group of DNA-binding compounds are those that interact with the minor 
groove of DNA. A minor groove binder that has been used clinically since the 1940s 
is the bis-amide pentamidine (21), an important drug in the treatment against a 
number of protozoal diseases, including those that cause pneumocystis pneumonia, 
leishmaniasis and African trypanosomiasis (sleeping sickness). From studies with 
several analogues it was suggested that the isohelical shape of the molecule is 
important for interaction with the minor groove [35]. Pentamidine, however, is also 
capable of inducing DNA cleavage, which is observed specifically in kinetoplast 
DNA [36], a complex network of circular DNA molecules found only in the 
mitochondrion of flagellate protozoa. The selectivity of pentamidine is due to the 
specific accumulation of the drug in these protozoa [37], but toxicity (nephro- and 
hepatotoxicity) remains a significant issue and is the cause for several side effects. 
 
 
Fig. 9. The structure of groove binders pentamidine (21) and [Zn((3-(4-dimethylaminophenyl)-
allyidene-1,2-diaminoethane)Cl2] (22). 
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Metals can greatly enhance the antibacterial activity of groove binders. For instance, 
the ligand bis(3-(4-dimethylaminophenyl)-allylidene)-1,2-diaminoethane, which is 
similar in shape to pentamidine, has MIC values of 250 and 125 µg/mL for B. subtilis 
and E. coli, respectively, but when complexed to Zn (complex 22, Fig 9), the MIC for 
both bacteria is 0.49 µg/mL [38]. Complex 22 was, however, not active on P. 
aeruginosa.  
Molecules that also have a similar crescent-shape as pentamidine are the naturally 
occurring antibiotics netropsin and distamycin A (23 and 24, Fig 10). These are 
polyamides belonging to the family of lexitropsins, which also includes several 
synthetic compounds. Netropsin (23) and dystamycin (24), both of which are 
produced by Streptomyces spp., contain two or three N-methylpyrrole rings, 
respectively (Fig. 10). The compounds can, depending on the concentration, bind 
DNA either in a 1:1 stoichiometry, or in a 2:1 stoichiometry in which with two 
molecules bind to DNA in an antiparallel orientation [39]. Lexitropsins have a wide 
range of activities, including antiviral, antibacterial, antifungal, antiparasitic and 
anticancer activity.  For instance, they have been shown to inhibit replication of the 
vaccinia virus, a virus closely related to cowpox virus [40], as well as HIV [41]. Other 
lexitropsins have been synthesised that are active against the fungi Aspergillus niger 
and Candida albicans and the bacteria S. aureus and Mycobacterium aurum [42, 43]. 
Netropsin and distamycin and are too toxic for clinical use, but it should be noted that 
some of their derivatives have been shown to have relatively low toxicity [44]. The 
latter study was focused on designing compounds with increased hydrophobicity, and 
it resulted in several compounds with high activity. It was not clearly established 
whether that was because of increased affinity or because of enhanced membrane 
permeability.  
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Fig. 10. Structures of netropsin (23) and distamycin (24) 
 
Of particular interest with lexitropsins is the potential for modulation of their 
sequence specificity. Netropsin and distamycin preferentially bind A/T rich DNA. 
However, this specificity can be altered by replacing the pyrrole rings (which 
preclude close contact with guanine) with imidazoles or hydroxypyrrole amino acids, 
thereby allowing interaction with G/C basepairs as well [45]. Further research 
allowed the design of a set of rules for interaction of lexitropsins with DNA, enabling 
the design of compounds interacting with specific DNA sequences [45]. Using this 
approach, lexitropsins have been designed inhibiting specific targets. An example of 
this is a number of compounds that target the sequence 5’-GGGACT-3’ and thereby 
inhibit binding of the eukaryotic transcription factor NF-kB [46], which regulates 
many genes involved in immune and inflammatory responses. Thus, even though this 
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target sequence is rather short, specificity was sufficiently high to affect regulation of 
a specific set of genes. 
 
4. Major Groove binders 
Major groove binders are less well researched than minor groove binders. There are a 
number of natural products known have major groove interacting elements (e.g. 
pluramycin and leinamycin), but the main contribution to their activity is through 
intercalation or alkylation (reviewed in Ref 47). A completely synthetic compound 
that was shown to bind specifically to the major groove is a dinuclear iron(II) 
supramolecular helicate [Fe2L3]4+, where L is an imine based ligand, (25, Fig. 11). 
Such helicates have diameters similar to α-helices and could thus be considered as 
peptide mimetics. The helicate [Fe2L3]4+ is produced as a mixture of two enantiomers 
(M and P), with the M enantiomer strongly inducing coiling of DNA [48]. We 
showed that [Fe2L3]4+ has activity against both Gram-positive and Gram-negative 
bacteria, with the former being more susceptible [49]. Interestingly, a copper double 
helicate compound of similar shape and size was not active, possibly because of a 
different mode of action or a difference in uptake of the compounds [49]. The activity 
of [Fe2L3]4+ was found to be rather moderate, with MIC values in the range of 32 
µg/mL, and solubility of the helicate was rather poor. Much better activity was 
achieved with so-called flexicates [50]. These compounds have a number of notable 
advantages over the aforementioned helicates, such as a significantly better solubility 
in water, and the ability to synthesise the complexes as optically pure enantiomers 
using a highly adaptable self-assembly approach. Importantly, the most active 
flexicate (from ligand 26; Fig. 11), was active against both Gram-negative as Gram-
! 18!
positive bacteria, with MIC values of 4-8 µg/mL, while displaying a low toxicity 
against nematodes (50% Lethal Concentration LC50 ~500 µg/mL). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 11. (A) Ligands 25 and 26 used in supramolecular peptide mimetics. (B) Structure of a flexicate 
(from ligand 26)  
 
5. DNA modifying compounds 
This class of compounds includes those that modify DNA by for instance alkylation, 
crosslinking or inducing DNA cleavage. There are a number of clinically used 
compounds in this group, mainly for the treatment of cancer. Examples of these are: 
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cisplatin, a DNA-crosslinking agent; bleomycin, a glycopeptide that induces breaks in 
DNA; and chlorambucil, an alkylating compound. Some of these have actually 
multiple targets, such as cisplatin (cis-[PtCl2(NH3)2)]), which was the first member of 
Pt(II) containing anti-cancer drugs. In mammalian cells, 95% of the drug binds to 
ribosomes or other targets [51], whereas in E. coli also several protein targets were 
identified [52].  
 
There are also a few DNA-modifying compounds that have been used for many years 
in the treatment of infections. One example is metronidazole, a nitroimidazole used 
particularly for treatment of infections with (micro)anaerobic bacteria (e.g. 
Bacteroides fragilis, Clostridium difficile and Helicobacter pylori) and protozoa (e.g. 
Trichomonas vaginalis, Giardia lamblia and Entamoeba histolytica) [53]. The 
compound itself is an inactive prodrug, but upon entry into cells it is reduced to a 
nitro radical that interacts with DNA, causing single and double strand breaks [54]. 
Only cells growing in anaerobic or microaerobic conditions have a redox potential 
sufficiently low to reduce metronidazole to its active form, explaining its activity on 
anaerobes in particular. A compound with (probably) a similar mode of action is 
nitrofurantoin, although this compound has been suggested to have other targets as 
well [55]. This is also a nitroheterocyclic compound that is mainly used in the 
treatment and prevention of urinary tract infections.  !
A compound named ELB-21 (27) has much more recently been identified. This is a 
pyrrolobenzodiazepine (PBD) dimer related to the natural product anthramycin. It 
binds covalently with DNA, leading to inter- and intrastrand covalent cross-links with 
DNA [56]. The compound fits the minor groove, and then forms covalent bonds with 
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guanine residues separated by three nucleotide basepairs [57], thus showing some 
sequence specificity. It is particularly active against Gram-positive bacteria, including 
(multidrug resistant) isolates of MRSA and VRE. The MIC values for ELB-21 are in 
the range of 0.008-0.06 µg/mL for MRSA [56] which is excellent, but toxicity of the 
compound is not yet clear. A similar compound, SJG-136, is in phase II clinical trials 
for testing as an antitumour compound [58]. Some clinical data on toxicity of this 
compound are thus available, suggesting that PDB dimers are effective at 
concentrations below the toxicity threshold [57]. A further development of the PBD 
dimers are PBD-biaryl conjugates; some of these also have excellent antimicrobial 
activity and, importantly, initial results indicate that these compounds are well 
tolerated in mice and that therefore their therapeutic index is much better than that of 
the PBD dimers [58]. 
 
Fig 12. The structure of ELB-21 (27) 
 
6. Resistance 
Several examples have been shown above on DNA-binding antimicrobial compounds. 
Yet only very few of these are used clinically, being metronidazole and 
nitrofurantoin. Do any of the other compounds mentioned, or any novel DNA-binding 
compounds have potential as therapeutics? For this several issues need to be 
considered, including the potential for resistance, toxicity and specificity.  
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As highlighted in the introduction, resistance is one of the major problems facing our 
healthcare system. In the initial stages of antibiotic discovery (1940s-1960s), many 
new classes were discovered but since that time most new antibiotics discovered are 
analogues of those same classes. Resistance to those appeared very quickly. Even 
when, after many years, a new class of antibiotic was being introduced in 2000 
(linezolid, an oxazolidinone), the first reports on linezolid resistance in VRE or 
MRSA appeared within about a year [59, 60]. Development of novel antibiotics is 
thus a continual arms race, and underexplored targets need to be utilised more.  
 
One question that could be raised is whether microorganisms can develop resistance 
rapidly against antibiotics that target DNA. In general, antibiotic resistance develops 
through a number of common mechanisms, which include altering the target, 
degradation or modification of the antibiotic, or decreasing the intracellular 
concentration of an antibiotic (either by reduced permeability or increased efflux). 
There may also be additional mechanisms of resistance that depend on the specific 
mode of action of the antimicrobial.  
 
The first of those options, altering the target, seems an unlikely mechanism for 
acquiring resistance against DNA-binding compounds, unless the target sequence is 
very specific (which is not the case for most DNA-binding compounds). The other 
mechanisms seem conceivable though and have indeed been observed. For instance, 
increased efflux can lead to resistance to the clinically used antibiotic metronidazole 
[61], and efflux is also used as a self-resistance mechanism for Streptomyces spp. 
producing daunorubicin and doxyrubicin [62] or netropsin (23) [63]. Similarly, 
intracellular accumulation can also be reduced through mutations in proteins involved 
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in influx of compounds, as exemplified by pentamidine (21) resistance in the 
protozoan Trypanosoma brucei [64, 65].  
 
Some DNA-binding compounds lead to damage in DNA, and resistance to such 
compounds has been shown to arise through DNA-repair mechanisms. For instance, 
overexpression of the DNA repair protein RecA leads to increased metronidazole 
resistance in B. fragilis [66], whereas production of UvrA-like excision repair proteins 
provide Streptomyces spp. self-resistance against daunorubicin and doxorubicin [67] 
and echinomycin (3) [68].  
 
The aforementioned metronidazole is a prodrug that is converted by specific 
reductases in anaerobic organisms to a DNA-damaging nitro radical. Mutations in 
these reductases [69], or production of alternative reductases [70] all can lead to 
metronidazole resistance. That is however a rather specific resistance mechanism, and 
in general the main modes of resistance to DNA-binding compounds thus appear to be 
through reduced intracellular accumulation (either reduced influx or increased efflux), 
or DNA-repair mechanisms.     
 
7. Toxicity and selectivity 
As with all drugs, toxicity and selectivity are important and related characteristics. 
Toxicity is naturally an obvious issue with DNA-binding compounds, as it might be 
difficult to discriminate between the DNA of the host and the pathogen. Some toxicity 
might have to be accepted though, in particular in the light of the ever-increasing 
threat of antibiotic resistance. For instance, there are already cases of totally drug 
resistant tuberculosis (TDR-TB), which are resistant against all first and second line 
! 23!
drugs. That is something that may occur as well with other bacterial infections, and 
one option that than needs to be considered is to use toxic antimicrobials that display 
considerable side effects. That is a policy already in use as exemplified by colistin, a 
membrane-active polymyxin that was abandoned in the 1970s because of its toxicity. 
However, it is now back in use clinically in for example cystic fibrosis patients who 
often suffer from severe lung infections with multidrug resistant bacteria [71].  
 
As shown above, many DNA-binding compounds are used in cancer therapy, but are 
still considered too toxic for use as antibacterials. The question is thus how increased 
selectivity can be achieved, thereby lowering host toxicity. Two general ways in 
which this can be established is either selective uptake of the compound in the 
pathogen, or selectivity of the compound for the target. More specific options are also 
possible, such as the activation of a prodrug as exemplified by the aforementioned 
antibiotic metronidazole (which is only activated in the strongly reducing conditions 
found in anaerobes [53]). Considering the transport of antibiotics, a significant 
amount of knowledge has been gathered on the efflux of these compounds and the 
resulting resistance. In contrast, very little is known about the uptake of antibiotics. If 
the compound is small and hydrophobic enough, compounds may enter through 
passive diffusion. In this case it is difficult to envisage selective uptake for such 
compounds, unless there is some specificity towards the type of lipids in the 
membrane, which is different between bacteria and eukarya. It is, however, 
conceivable to establish selective uptake for those compounds that require specific 
transporters. An example that has already been mentioned above for the minor groove 
binder pentamidine (21), which in the protozoa T. brucei is mainly taken up through 
the P2 aminopurine transporter [64] and aquaglyceroporin 2 [65]. For other 
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antimicrobials, conjugation to specific molecules could ensure a more selective 
uptake. For instance, vancomycin conjugated to chitosan-nanoparticles has been 
shown to be effective against drug-resistant S. aureus [72], whereas fosmidomycin 
fused to the cell-penetrating peptide octa-arginine increased showed improved 
efficacy in both protozoal and bacterial species, being Plasmodium spp. and 
Mycobacterium spp., respectively [73].  
 
Another strategy that has gained a fair amount of attention, and also called a “Trojan 
horse” approach, is to create conjugates with siderophores. In many bacteria 
siderophores play a key role in the uptake of iron, an essential nutrient for most 
bacteria [74]. They have a low molecular weight (<1500 Daltons), and are secreted by 
bacteria when availability of free iron is low. Siderophores have a very high affinity 
for iron and, after complexing insoluble or protein-bound iron, are imported back into 
the cell through receptor-specific transporters. Several conjugates of antimicrobials 
with siderophore-like compounds have been made, with mixed results. One successful 
example is the conjugation of the mycobacterial siderophore mycobactin to 
artimisinin [75]. Artimisinin is an antimalarial and by itself not active against 
Mycobacterium tuberculosis, the causative agent of tuberculosis. However, a 
mycobactin-artimisinin conjugate was highly active against M. tuberculosis, including 
multidrug-resistant strains, and also retained activity against malaria. Other examples 
include siderophore-fluoroquinolone [76], and siderophore-beta-lactam conjugates 
[77], showing enhanced activity against Gram-positive and Gram-negative bacteria. 
From these examples it is clear that enhanced uptake can be achieved through various 
methods such as conjugation to peptides, nanoparticles or siderophores. A 
requirement is of course that, if specific transporters are utilised, these transporters 
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should be fairly promiscuous to allow for the transport of conjugates. The examples 
above however demonstrate that this is feasible with e.g. the siderophores, as 
enhanced uptake has been demonstrated for a wide range of compounds ranging from 
fairly simple beta-lactams to the more complex artimisinin and vancomycin. 
 
A second approach to enhance selectivity of DNA binding compounds is through 
increasing sequence specificity. Some DNA-binding compounds already show some 
degree of sequence specificity, such as the minor groove binders pentamidine (21), 
netropsin (23) and distamycin A (24), which have a preference for AT-rich DNA. 
Plasmodium falciparum DNA is very AT-rich (>80%), and it was speculated that that 
was the reason for the high activity of some of these compounds against malaria [78]. 
Also, as mentioned before sequence specificity of the lexitropsins can be manipulated, 
following a specific set of rules, by replacing the pyrrolo rings with imidazoles or 
hydroxypyrrole amino acids [45]. Through work in the group of Dervan in particular, 
it was demonstrated that hairpin-shaped polyamides, connecting two three-ringed 
lexitropsins with a γ-butyric acid linker could be designed to recognise sequences 
with high affinity and specificity [45]. Such molecules bind in the minor groove in an 
antiparallel fashion, with pyrrole (Py)-imidazole (Im) pairing targeting C-G, Im-Py 
targeting G-C, and Py/Py targeting A-T or T-A. The length of the sequences 
recognised is however still relatively short, being 6-7 nucleotides [45, 79]. Such 
sequences do occur frequently in genomes of either humans or pathogens, but it is 
sufficient to target specific genes, as demonstrated by lexitropsins specifically 
inhibiting the eukaryotic transcription factor NF-kB [46] or RNA polymerase II in 
human cells [80]. 
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Another approach recently taken in sequence-specific inhibition is by designing 
distamycin-peptide conjugates [81]. In that study, the authors focused on the DNA-
interacting protein E2 from the human papillomavirus (HPV, the main causative agent 
of cervical cancer). This protein plays a key role in viral DNA replication and is thus 
attractive for developing antivirals. E2 is a transcription regulator that interacts with 
the major groove of DNA, but a peptide corresponding to the DNA-binding region of 
E2 has only low affinity. However, tethering that peptide to distamycin greatly 
enhanced its affinity [81], thus showcasing an interesting strategy for developing 
novel therapeutics. Similarly, intercalators have also been used to tether peptides. 
These include conjugates of the intercalator [Rh(phi)2(phen')]3+ (phi  =  9,10-
phenanthrenequinone diimine; phen' = 5-(amidoglutaryl)-1,10-phenanthroline] with 
an α-helical peptide derived from the bacteriophage P22 repressor in order to explore 
peptide-DNA interactions [82]. It was demonstrated that these interacted strongly 
with DNA, and that changing the amino acid sequence of the peptide could also alter 
the recognition sequence. The aim in that study was not directly to develop bioactive 
compounds, but it did demonstrate the potential of such peptide-intercalator 
conjugates in developing sequence-specific molecules, which could be utilized to 
inhibit a particular, or a group of genes, in pathogenic microorganisms. 
 
8. Concluding remarks 
In order to stay ahead in the arms race against bacterial resistance there is a continual 
need to identify novel antimicrobials, and one strategy to achieve that is to go for 
targets that have not been utilised fully before. As is clear from this review, DNA as a 
target for antimicrobials is rather underexplored, with only a few antibacterials in 
clinical use (metronidazole, nitrofurantoin), plus a few compounds that are being used 
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for protozoa, such as pentamidine. New compounds with good activity are however 
on the horizon such as the aforementioned ELB-21 (27). An interesting development 
is the addition of a metal to create DNA-binding complexes, which can provide 
additional geometric possibilities resulting from coordinate metal centres (4, 5 or 6 
compared to 4-coordinate carbon). Compounds that contain hydroxyl, carboxylic 
acid, and amine groups offer excellent donor atoms to form coordination bonds. 
These can be classic polypyridyl ligands (e.g. 1,10-phenanthroline, 2,2 bipyridine), 
but also existing antibiotics such as ciprofloxacin may prove very useful in this. 
Coordination may also improve solubility, which in turn may increase biological 
activity. Toxicity and selectivity are issues that do play a role with DNA-binding 
compounds, but as shown above there are strategies to increase the therapeutic index, 
through either increasing selective uptake of compounds in microbes, or through 
development of DNA binding compounds that are sequence-specific. Rapid 
development of resistance is another factor that hampers the identification of novel 
antibiotics generally, and that is something that also cannot be avoided with DNA-
binding compounds. After all, the short generation time of some bacteria (20-30 
minutes) provides plenty of scope for acquiring resistance genes or mutations that 
lead to resistance, in particular when that is compared to the speed at which novel 
antibiotics are introduced into the market (years). Expanding our arsenal with novel 
antimicrobials with barely utilised cellular targets may help us to stay ahead and 
prevent entering into a post-antibiotic era. 
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